News

• I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
  04/27/2020 / 22:01 - GlobeNewswire
•  
• MOR106 clinical development in atopic dermatitis stopped for futility
  10/28/2019 / 21:45 - GlobeNewswire
•  
• Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
  04/23/2019 / 22:02 - GlobeNewswire
•  
• Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
  04/23/2019 / 22:01 - GlobeNewswire
•  
• Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
  09/13/2018 / 22:04 - GlobeNewswire
•  
• Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106
  09/13/2018 / 22:01 - GlobeNewswire
•  
• MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner
  09/12/2018 / 22:03 - GlobeNewswire
•  
• MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner
  09/12/2018 / 22:01 - GlobeNewswire
•  
• MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
  07/19/2018 / 07:17 - GlobeNewswire
•  
• MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner
  07/19/2018 / 07:15 - GlobeNewswire
•  
• Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients
  05/01/2018 / 22:03 - GlobeNewswire
•  
• Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atopic dermatitis patients
  05/01/2018 / 22:01 - GlobeNewswire
•  
• Nasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock Market
  04/19/2018 / 22:25 - GlobeNewswire
•  
• Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego
  02/17/2018 / 10:02 - GlobeNewswire
•  
• Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego
  02/17/2018 / 10:00 - GlobeNewswire